| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A new ‘golden age’ for the antitubercular target InhA
|
Rožman, Kaja
|
|
2017
|
22 |
3 |
p. 492-502
|
artikel
|
| 2 |
Antituberculosis drugs: reducing efflux=increasing activity
|
Rodrigues, Liliana
|
|
2017
|
22 |
3 |
p. 592-599
|
artikel
|
| 3 |
A summary of some EU funded Tuberculosis drug discovery collaborations
|
Ekins, Sean
|
|
2017
|
22 |
3 |
p. 479-480
|
artikel
|
| 4 |
Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB)
|
Ekins, Sean
|
|
2017
|
22 |
3 |
p. 555-565
|
artikel
|
| 5 |
Contents page 1
|
|
|
2017
|
22 |
3 |
p. i
|
artikel
|
| 6 |
Contents page 2
|
|
|
2017
|
22 |
3 |
p. ii
|
artikel
|
| 7 |
DNA topoisomerase I and DNA gyrase as targets for TB therapy
|
Nagaraja, Valakunja
|
|
2017
|
22 |
3 |
p. 510-518
|
artikel
|
| 8 |
Drug targeting of heme proteins in Mycobacterium tuberculosis
|
McLean, Kirsty J.
|
|
2017
|
22 |
3 |
p. 566-575
|
artikel
|
| 9 |
How can nanoparticles contribute to antituberculosis therapy?
|
Costa-Gouveia, Joana
|
|
2017
|
22 |
3 |
p. 600-607
|
artikel
|
| 10 |
Identification and validation of novel drug targets in Mycobacterium tuberculosis
|
Singh, Vinayak
|
|
2017
|
22 |
3 |
p. 503-509
|
artikel
|
| 11 |
Learning from the past for TB drug discovery in the future
|
Mikušová, Katarína
|
|
2017
|
22 |
3 |
p. 534-545
|
artikel
|
| 12 |
New prodrugs against tuberculosis
|
Mori, Giorgia
|
|
2017
|
22 |
3 |
p. 519-525
|
artikel
|
| 13 |
Raising awareness of the importance of funding for tuberculosis small-molecule research
|
Riccardi, Giovanna
|
|
2017
|
22 |
3 |
p. 487-491
|
artikel
|
| 14 |
Recent developments in natural product-based drug discovery for tuberculosis
|
Dong, Maryline
|
|
2017
|
22 |
3 |
p. 585-591
|
artikel
|
| 15 |
Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors
|
Piton, Jérémie
|
|
2017
|
22 |
3 |
p. 526-533
|
artikel
|
| 16 |
Target-based approaches for the discovery of new antimycobacterial drugs
|
Borsari, Chiara
|
|
2017
|
22 |
3 |
p. 576-584
|
artikel
|
| 17 |
Targeting tuberculosis using structure-guided fragment-based drug design
|
Mendes, Vitor
|
|
2017
|
22 |
3 |
p. 546-554
|
artikel
|
| 18 |
The implications of model-informed drug discovery and development for tuberculosis
|
Muliaditan, Morris
|
|
2017
|
22 |
3 |
p. 481-486
|
artikel
|
| 19 |
Tuberculosis drug discovery needs public–private consortia
|
Cole, Stewart T.
|
|
2017
|
22 |
3 |
p. 477-478
|
artikel
|
Tijdschrift beschrijving